Cargando…

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

BACKGROUND AND OBJECTIVES: Molecular genetic testing using tissue biopsies can be challenging for patients due to unfavorable tumor sites, the invasive nature of a tissue biopsy, and the added time of booking a repeat biopsy (re-biopsy). Centers in Canada have found insufficient tissue rates to be a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Yuti P., Husereau, Donald, Leighl, Natasha B., Melosky, Barbara, Nam, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700634/ https://www.ncbi.nlm.nih.gov/pubmed/34940080 http://dx.doi.org/10.3390/curroncol28060441

Ejemplares similares

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Feasibility of Comprehensive Genomic Profiling (CGP) in Real-Life Clinical Practice
por: Nibid, Lorenzo, et al.
Publicado: (2023)

Imobilization of trypsin in films of PVA/CGP
por: Moreira, Bruna, et al.
Publicado: (2014)

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Detection of the secondary, low-affinity β(1)-adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP
por: Gherbi, K, et al.
Publicado: (2014)

Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data
por: John, Ani, et al.
Publicado: (2021)

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
por: Graham, Donna M., et al.
Publicado: (2014)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

Liquid biopsy in NSCLC: a new challenge in radiation therapy
por: Perillo, Annarita, et al.
Publicado: (2021)

The Neuroprotector Benzothiazepine CGP37157 Extends Lifespan in C. elegans Worms
por: García-Casas, Paloma, et al.
Publicado: (2019)

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
por: Raphael, Ari, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists
por: Sanyal, Chiranjeev, et al.
Publicado: (2019)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
por: Ezeife, Doreen A., et al.
Publicado: (2022)

The gland localized CGP1 controls gland pigmentation and gossypol accumulation in cotton
por: Gao, Wei, et al.
Publicado: (2020)

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
por: Pasini, Luigi, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
por: Mellert, Hestia, et al.
Publicado: (2021)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992)

Effect of GABA(B) Receptor Antagonist (CGP35348) on Learning and Memory in Albino Mice
por: Gillani, Quratulane, et al.
Publicado: (2014)

Therapeutic potential of blocking GAPDH nitrosylation with CGP3466b in experimental autoimmune encephalomyelitis
por: Godfrey, Wesley H., et al.
Publicado: (2023)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
por: Elvin, Julia A., et al.
Publicado: (2017)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent
por: Han, Hyun-Wook, et al.
Publicado: (2018)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC
por: Li, Yilin, et al.
Publicado: (2023)

Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression
por: Collison, Kate S., et al.
Publicado: (2018)

Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy
por: McMullen, James R.W., et al.
Publicado: (2017)

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients
por: Sanchez-Cabrero, Darío, et al.
Publicado: (2023)

Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors
por: Jackson, Leisa P., et al.
Publicado: (2020)

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Sama, Srikar, et al.
Publicado: (2022)

GABA(B) Receptor Antagonist CGP46381 Inhibits Form-Deprivation Myopia Development in Guinea Pigs
por: Cheng, Zhen-Ying, et al.
Publicado: (2015)

Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
por: Cores, Ángel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u5hrpakan1p96u9d5idm7fkq07